corticotropin

Human CRF acetate is a chemical compound that effectively stimulates the synthesis and secretion of adrenocorticotropin in the anterior pituitary.

α-Helical Corticotropin Releasing Factor (9-41) is a corticotropin releasing factor (CRF) antagonist that reduces plasma growth hormone (GH) levels in vivo [1] [2].

α-Helical Corticotropin Releasing Factor (12-41), a 30-amino-acid α-helical analogue of corticotropin releasing factor hormone (CRF), is a hypothalamic hormone that promotes adrenocorticotrophic hormone (ACTH) secretion. This compound counteracts CRF's stimulatory effect on ACTH secretion [1] [2].

[DPro5] Corticotropin Releasing Factor, human, rat, a selective R2 agonist of corticotropin-releasing factor hormone (CRF), is a hypothalamic hormone that prompts the release of adrenocorticotropic hormone (ACTH) and β-endorphin. Unlike typical agents, it does not induce anxiogenic effects but instead influences learning and memory processes in rats [1].

Corticotropin Releasing Factor, ovine [Met(O)21], is a hypothalamic hormone isolated from ovine hypothalamic extracts. It functions by stimulating the secretion of adrenocorticotrophic hormone (ACTH) [1].

β-Corticotropin (swine), a synthetic analog of the peptide hormone corticotropin (ACTH), induces steroid release [1] [2].

[Tyr^0] Corticotropin Releasing Factor, ovine, is a hypothalamic hormone sourced from sheep that prompts the secretion of adrenocorticotropic hormone (ACTH) and β-endorphin [1] [2].

Corticotropin-releasing factor human (Human CRF; Human corticotropin-releasing factor) is an immunomodulatory neuropeptide that releases ACTH from the anterior pituitary, stimulates the sympathetic nervous system and adrenal medulla, reduces hyperpolarizations, and acts as a functional antagonist of inflammatory mediators.

Corticotropin-releasing factor (human) acetate stimulates to synthesize and secret adrenocorticotropin in the anterior pituitary.

Adrenocorticotropic Hormone (ACTH) (1-39) human (TFA), a member of the melanocortin family, is a melanocortin receptor agonist that stimulates corticosteroid production by the adrenals; melanocortin receptors are also located in the central nervous system (CNS) and on immune cells.

ACTH 1-14 acetate(25696-21-3 free base) (Adrenocorticotropic Hormone Fragment 1-14 acetate) is a fragment of adrenocorticotrophin, which regulates cortisol and androgen production.Adrenocorticotropic hormone (ACTH), also known as corticotropin, is produced and secreted by the anterior pituitary gland. ACTH is an important component of the hypothalamic-pituitary-adrenal axis as a response to biological stress.

Astressin acetate is an antagonist of corticotropin releasing factor (CRF) with low affinity for the CRF binding protein and high affinity for the cloned pituitary receptor(Ki = 2 nM).

Acth (1-4) is the ACTH N-terminal tetrapeptide.

Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011). Urocortin III is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin II , frog sauvagine, and piscine urotensin I.1 Human urocortin III shares 90, 40, 37, and 21% identity to mouse urocortin III , mouse urocortin II , human urocortin , and mouse urocortin, respectively. Urocortin III selectively binds to type 2 CRF receptors (Kis = 21.7, 13.5, and >100 nM for rat CRF2α, rat CRF2β, and human CRF1, respectively). It stimulates cAMP production in CHO cells expressing rat CRF2α and mouse CRF2β (EC50s = 0.16 and 0.12 nM, respectively) as well as cultured anterior pituitary cells expressing endogenous CRF2β. Urocortin III is co-released with insulin to potentiate glucose-stimulated somatostatin release in vitro in human pancreatic β-cells.2 In vivo, urocortin III reduces food intake in a dose- and time-dependent manner in mice with a minimum effective dose (MED) of 0.3 nmol/animal.3 It increases swimming time in a forced swim test in mice, indicating antidepressant-like activity.4 References1. Lewis, K., Li, C., Perrin, M.H., et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl. Acad. Sci. U.S.A. 98(13), 7570-7575 (2001).2. van der Meulen, T., Donaldson, C.J., Cáceres, E., et al. Urocortin3 mediates somatostatin-dependent negative feedback control of insulin secretion. Nat. Med. 21(7), 769-776 (2015).3. Pelleymounter, M.A., Joppa, M., Ling, N., et al. Behavioral and neuroendocrine effects of the selective CRF2 receptor agonists urocortin II and urocortin III. Peptides 25(4), 659-666 (2004).4. Tanaka, M., Kádár, K., Tóth, G., et al. Antidepressant-like effects of urocortin 3 fragments. Brain Res. Bull. 84(6), 414-418 (2011).

Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I.1 Mouse urocortin II shares 34 and 42% sequence homology with rat CRF and urocortin . It is expressed in mouse paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and in motor nuclei of the brainstem and spinal ventral horn. Urocortin II selectively binds to CRF1 over CRF2 receptors (Kis = 0.66 and >100 nM, respectively) and induces cAMP production in CHO cells expressing CRF2 (EC50 = 0.14 nM). In vivo, urocortin II suppresses nighttime food intake by 35% in rats when administered intracerebroventricularly at a dose of 1 μg. Urocortin II (0.1 and 0.5 μg, i.c.v) stimulates fecal pellet output, increases distal colonic transit, and inhibits gastric emptying in mice.2References1. Reyes, T.M., Lewis, K., Perrin, M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98(5), 2843-2848 (2001).2. Martinez, V., Wang, L., Million, M., et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25(10), 1733-1744 (2004). Urocortin II is a neuropeptide hormone and member of the corticotropin-releasing factor (CRF) family which includes mammalian CRF , urocortin , urocortin III , frog sauvagine, and piscine urotensin I.1 Mouse urocortin II shares 34 and 42% sequence homology with rat CRF and urocortin . It is expressed in mouse paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and in motor nuclei of the brainstem and spinal ventral horn. Urocortin II selectively binds to CRF1 over CRF2 receptors (Kis = 0.66 and >100 nM, respectively) and induces cAMP production in CHO cells expressing CRF2 (EC50 = 0.14 nM). In vivo, urocortin II suppresses nighttime food intake by 35% in rats when administered intracerebroventricularly at a dose of 1 μg. Urocortin II (0.1 and 0.5 μg, i.c.v) stimulates fecal pellet output, increases distal colonic transit, and inhibits gastric emptying in mice.2 References1. Reyes, T.M., Lewis, K., Perrin, M.H., et al. Urocortin II: A member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl. Acad. Sci. U.S.A. 98(5), 2843-2848 (2001).2. Martinez, V., Wang, L., Million, M., et al. Urocortins and the regulation of gastrointestinal motor function and visceral pain. Peptides 25(10), 1733-1744 (2004).

Argipressin (Arg8-vasopressin) inhibits central corticotropin-releasing hormone. Argipressin acts as a repressor in the regulation of central CRH levels. 5A2-SC8 is an APC-dependent protein.

CRF(6-33)(human) TFA is a competitive inhibitor of the Corticotropin-Releasing Factor Binding Protein (CRF-BP), selectively interacting with CRF-BP without affecting post-synaptic Corticotropin-Releasing Factor receptors, and demonstrates an anti-obesity effect [1] [2].

Urocortin II, mouse, is a selective and potent endogenous peptide agonist for the type-2 corticotropin-releasing factor (CRF2) receptor, displaying K_i values of 0.66 nM for CRFR2 and >100 nM for CRFR1, signifying its high specificity. It engages CRF2 receptors through mechanisms dependent on cAMP PKA and Ca2+ CaMKII. Additionally, Urocortin II, mouse is localized in specific regions of the central nervous system, influencing central neurons that process visceral sensory information and regulate autonomic functions [1] [2] [3].

Urocortin III (human) is a corticotropin-releasing factor (CRF)-related peptide that primarily interacts with and activates the CRF receptor type 2 (CRF-R2), showing a specific distribution in the central nervous system and periphery. It selectively binds to type 2 CRF receptors with dissociation constants (Ki values) of 13.5 nM for mouse CRF2β, 21.7 nM for rat CRF2α, and >100 nM for human CRF1, indicating a strong preference for CRF-R2 over CRF1. Additionally, Urocortin III (human) plays a crucial role in the somatostatin-dependent negative feedback mechanism regulating the secretion of Insulin (human).

(Tyr0)-Urocortin, rat, serves as a high-affinity agonist for both corticotropin-releasing factor receptor type 1 (CRF-R1) and type 2 (CRF-R2), demonstrating inhibitory binding constants (Ki) of 1-2 nM [1].

[Asu1,6-Arg8]Vasopressin is a vasopressin agonist that enhances cyclic AMP accumulation and adrenocorticotropic hormone (ACTH) release triggered by corticotropin-releasing factor (CRF) in cultured rat anterior pituitary cells [1] [2].

(D-Phe12,Nle21,38,α-Me-Leu37)-CRF (12-41) (human, rat) is a corticotropin-releasing factor (CRF) antagonist that counteracts the inhibitory effects of IL-1a on luteinizing hormone (LH) production [1].

ACTH (7-38) (human) is a fragment (7-38) of the full human adrenocorticotropic hormone (ACTH (1-39)), also known as corticotropin inhibitory peptide (CIP). It functions as an antagonist to the ACTH receptor and lacks corticosteroid activity [1].

Codactide is a synthetic octadecapeptide exhibiting corticotropin-like activity [1].